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Abstract
Background: Osteoarthritis (OA) is a common disease of older individuals that impacts detrimentally on the quality
and the length of life. It is characterised by the painful loss of articular cartilage and is polygenic and multifactorial.
Genome-wide association scans have highlighted over 90 osteoarthritis genetic signals, some of which reside within or
close to highly plausible candidate genes. An example is an association to polymorphisms within and adjacent to the
matrix Gla protein gene MGP. We set out to undertake a functional study of this gene.
Methods: Nucleic acid was extracted from cartilage, infrapatellar fat pad, synovium, trabecular bone, trapezium and
peripheral whole blood from OA patients and also from mesenchymal stem cells (MSCs) subjected to chondrogenesis.
Expression of MGP was measured by quantitative PCR (qPCR), RNA-sequencing and allelic expression imbalance (AEI)
analysis. Matrix Gla protein was depleted in chondrocytes by knocking down MGP expression using RNA interference
(RNAi) and the effect on a range of genes assessed by qPCR.
Results: MGP is expressed in joint tissues, blood and chondrocytes cultured from MSCs. There is a higher expression in
diseased versus non-diseased cartilage. Polymorphisms that are associated with OA also correlate with the expression
of MGP, with the OA risk-conferring allele showing significantly reduced expression in cartilage, fat pad and synovium
but increased expression in blood. Depletion of Matrix Gla protein had a significant effect on the majority of genes
tested, with an increased expression of catabolic genes that encode enzymes that degrade cartilage.
Conclusions: MGP expression is subject to cis-acting regulators that correlate with the OA association signal. These are
active in a range of joint tissues but have effects which are particularly strong in cartilage. An opposite effect is observed
in blood, highlighting the context-specific nature of the regulation of this gene’s expression. Recapitulation of the genetic
deficit in cartilage chondrocytes is pro-catabolic.
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Introduction
Osteoarthritis (OA) is a highly polygenic musculoskeletal
disorder that is common in most populations and princi-
pally affects older individuals. It is characterised by a grad-
ual, focal loss of the articular cartilage with concurrent and
consequential alterations to other joint tissues [1]. Patients
initially present with chronic joint pain and loss of normal
joint function with surgical intervention often required in
severe cases of the disease. OA therefore impacts on the
quality of life, but it can also shorten the length of life [2].
Genome-wide association scans (GWAS) have reported
over 90 independent genome-wide significant risk alleles
for OA [3–7]. Most of these studies have focused on hand,
knee or hip OA, with disease at these sites having a par-
ticularly large impact on the health of the patient and on
health care systems.
The principal translational goal of OA GWAS studies is
the generation of new knowledge regarding disease aeti-
ology that can then be directed to treatment development.
In this regard, the association with hand OA of functional
polymorphism at the MGP locus was very noteworthy [8].
This gene codes for matrix Gla protein, which is secreted
by cartilage chondrocytes into the synovial joint space,
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where it regulates the levels of free calcium via the affinity
of its γ-carboxyglutamic acid (Gla) residues for calcium
ions [9]. In so doing, matrix Gla protein inhibits ectopic
calcification of the joint. The OA association was to single
nucleotide polymorphism (SNP) rs4764133 (C > T), which
is located upstream of MGP and which correlated with al-
tered expression of the gene in cartilage; the OA-risk con-
ferring T allele of rs4764133 showed reduced expression
relative to the non-risk C allele [8]. This implies that the
genetic susceptibility at this locus acts by lowering the level
of MGP expression, which leads to reduced amounts of
matrix Gla protein. This would be permissive to ectopic
cartilage calcification and as such may be the mechanism
by which this association signal acts to increase OA risk.
This genetic data supports the application in OA of com-
pounds that could attenuate this calcification, such as vita-
min K which is involved in the biosynthesis of Gla-rich
proteins [10].
The compelling and potentially translatable nature of the
MGP genetic association report prompted us to undertake
a more detailed molecular analysis of this signal. We set
out to replicate and then expand on the MGP expression
study into other joint tissues and cells from patients. We
also modelled the impact of the rs4764133 risk-conferring
allele by knocking down MGP in cartilage chondrocytes
and assessing effects on anabolic, catabolic, and hyper-
trophic genes.
Materials and methods
OA patients
Joint tissue samples were obtained from patients undergo-
ing orthopaedic surgical procedures at the Newcastle upon
Tyne NHS Foundation Trust hospitals. Samples were
collected from two categories of patient: (1) those with
primary hip or knee OA who had undergone joint replace-
ment surgery and (2) those with primary hand OA who
had undergone a trapeziectomy. In total, we accessed and
studied tissue samples from a total of OA 165 patients.
For knee and hip OA patients, we collected macroscop-
ically normal cartilage (distal from the lesion and therefore
avoiding areas of fibrillated tissue), infrapatellar fat pad,
synovium and trabecular bone (which were taken from
non-sclerotic areas). For some of our knee and hip
patients, more than one joint tissue type was available for
analysis. For hand OA patients, cartilage could not be sep-
arated from subchondral bone due to the small size of the
trapeziectomy samples, and as such, subchondral bone
with its attached cartilage (osteochondral samples) was
collected. We also collected whole peripheral blood sam-
ples from some of our hip and knee OA patients just prior
to their surgery, using EDTA vacutainers for DNA extrac-
tion and Tempus™ tubes for RNA extraction (Thermo-
Fisher Scientific). Further details regarding the patients
can be found in Additional file 1: Table S1.
Nucleic acid extractions
Tissue samples were stored at − 80 °C and ground to a
powder using a mixermill (Retsch Limited) under liquid
nitrogen. For cartilage, bone and trapeziectomy samples,
RNA was extracted using TRIzol (Life Technologies) and
DNA was extracted using the E.Z.N.A. Tissue DNA isola-
tion kit (Omega Biotek, VWR). For synovium and fat pad,
DNA and RNA were extracted using the E.Z.N.A. DNA/
RNA isolation kit (Omega Biotek, VWR). For blood, DNA
was extracted using the QIAamp DNA blood mini kit
(Qiagen) and RNA extracted using the Tempus™ Spin
RNA isolation kit (ThermoFisher Scientific).
Quantitative gene expression
cDNA synthesis and quantitative PCR (qPCR) were per-
formed as described previously [11]. Predesigned TaqMan
assays (Integrated DNA Technologies) or assays designed
using the Roche probe library system were used to quantify
expression of the housekeeping genes HPRT1, 18S and
GAPDH and 12 target genes. The relative gene expression
was calculated by the 2−ΔCt method, where ΔCt is the mean
Ct value of the three housekeeping genes subtracted from
the Ct value of the target gene of interest. For target
gene RUNX2, two qPCR assays were used: one target-
ing exons 6–7, measuring both the main isoforms of
the gene (termed RUNX2all), and one targeting exons
1–2, which measures the longer isoform of the gene
(termed RUNX2long) [12].
Mesenchymal stem cell (MSC) chondrogenesis
Immortalised human MSCs derived from adipose tissue
(SCRC-4000, ATCC) were subjected to V-bottom 96-well-
plate pellet chondrogenesis for 21 days, as described previ-
ously [13]. Human bone marrow MSCs from a female
donor aged 24 years (Lonza Biosciences) were cultured,
phenotype tested and subjected to V-bottom 96-well-plate
pellet chondrogenesis for 7 days, as described previously
[14]. In each case, three pellets were analysed at each time
point, representing three independent differentiations.
RNA was extracted from each pellet using TRIzol (Life
Technologies), cDNA synthesised and MGP expression
measured by qPCR with three technical repeats per cDNA.
RNA-sequencing (RNA-seq)
The expression of MGP was assessed using RNA-seq
data that we had previously generated from the cartilage
of ten hip OA patients and six patients who had under-
gone hip replacement due to a neck-of-femur (NOF)
intracapsular fracture [15]. The NOF patients showed no
signs or symptoms of hip OA, and their cartilage was
macroscopically intact and with no lesions. Transcripts
per million (TPM) values were extracted using R (http://
www.R-project.org/) and visualised using the ggplot2 li-
brary in R. Differential expression analysis between OA
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and NOF was carried out with the Bioconductor package
DESeq2 [16].
Genotyping
We chose to analyse MGP transcript SNP rs4236 (T >
C, OA risk allele = C, minor allele frequency = 0.37) as
the difference in expression between its risk and non-
risk alleles was the largest of those SNPs investigated in
the original study [8]. The SNP was genotyped by pyro-
sequencing using the primers listed in Additional file 2:
Table S2. The assay was designed using PyroMark assay
design 2.0 (Qiagen), and the sequencing was performed
using the PyroMark Q24 Advanced platform (Qiagen).
Allelic expression imbalance (AEI)
AEI at rs4236 heterozygotes was quantified by pyrose-
quencing, using the methodology described above and
the same primers. The sequences were generated auto-
matically and an output of allelic ratio was produced
using PyroMark Advanced software (Qiagen). For each
cDNA and DNA sample from a heterozygote, PCR reac-
tions were formed in triplicate. Samples were excluded
from the analysis if the values between the PCR repli-
cates differed by > 5%. The respective cDNA and DNA
were analysed concurrently and allelic expression of
cDNA was normalised to its corresponding DNA.
RNA interference (RNAi)
Primary human articular chondrocytes (HACs) were
isolated by enzymatic digestion of OA knee cartilage,
cultured, and RNAi was then performed, essentially as
described previously [11, 17]. The cells were seeded in
6-well plates at a density of 350,000 cells per well. After
24 h, cells were transfected with 50 nM Dharmacon
ON-TARGETplus SMARTpool small interfering RNA
(siRNA) targeted against MGP (L-009770-00) or a non-
targeting scrambled siRNA control (D-001810-10-20).
Cells were harvested 48 h after transfection, and RNA
and protein were extracted using the Nucleospin RNA/
protein kit (Macherey-Nagel, supplied by Thermo-
Fisher). Gene expression was assessed by qPCR using
cDNA synthesised from RNA extracted from each well,
with a minimum of four technical repeats per gene ana-
lysed. For immunoblot analysis of matrix Gla protein
depletion, 10 μg of total protein was resolved on 10%
(w/v) SDS–polyacrylamide gels. Blots were probed with
anti-matrix Gla protein (α-MGP; Proteintech 10734-1-
AP) or anti-GAPDH (α-GAPDH; Cell Signalling Tech-
nologies) antibodies. Matrix Gla protein depletion was
quantified using ImageJ software [18] by normalising to
levels of α-GAPDH.
Statistical analyses
For quantitative gene expression analyses, P values were
calculated using a Mann-Whitney 2-tailed exact test. For
RNA-seq, hypothesis testing was performed using the
DESeq2 implementation of the Wald test. For AEI, P
values were calculated using a Mann-Whitney 2-tailed
exact test. For gene expression analyses in the RNAi experi-
ment, P values were calculated using a Student’s 2-tailed t
test. For quantification of MGP protein abundance, P
values were calculated using a Student’s 2-tailed t test.
Results
Expression of MGP
Using qPCR, we initially assessed the expression of MGP
in five joint tissues from our OA patients: cartilage (n =
22), fat pad (n = 9), synovium (n = 13), trabecular bone
(n = 14), and trapezium (n = 8). We also examined expres-
sion in peripheral blood (n = 15 patients). MGP was
expressed in all samples, with the highest level being in
cartilage and the lowest in blood (Fig. 1a). We next com-
pared the level of MGP expression between hip cartilage
from OA (n = 10) and NOF (n = 6) patients in our RNA-
seq data. The gene was expressed in both patient groups
with a non-significant (P = 0.08) higher level in OA
(Fig. 1b). Using this RNA-seq data, we then assessed the
relative expression levels of the transcript isoforms of
MGP. The gene has four isoforms, three of which are pro-
tein coding (isoforms 201, 203 and 204) and one which is
not (isoform 202). All were expressed in cartilage, with iso-
form 203, which codes for the canonical form of the pro-
tein, being most abundant (Fig. 1c). We next assessed the
expression of MGP during pellet chondrogenesis, which
was performed on an immortalised human MSC cell line
(Fig. 1d) and on primary MSCs from a human donor
(Fig. 1f). The gene showed an induction in both cell types,
with a particularly striking increase in expression during
chondrogenesis in the cell line.
Allelic expression imbalance
In the GWAS report for MGP, the authors used allelic
expression imbalance (AEI) analysis to demonstrate that
the OA risk conferring T allele of rs4764133 correlated
with reduced expression of the gene in cartilage [8]. To
do this, they studied three MGP transcript SNPs
(rs4236, rs1049897 and rs1800801) that are in high link-
age disequilibrium (LD) with each other and with
rs4764133 (all pair wise r2 values > 0.85). Each transcript
SNP had shown significant evidence of AEI. We chose
to use rs4236 (T > C; r2 = 0.89 relative to rs4764133; T
allele of rs4764133 is equivalent to the C allele of
rs4236), the SNP that showed the largest degree of AEI
in that initial report (39.6% of the OA risk-conferring C
allele versus 60.4% of the non-risk T allele). This SNP is
located within the final exon of MGP and is present in
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all four transcript isoforms. We genotyped our patients
for rs4236 to identify heterozygotes. We then investi-
gated AEI in cartilage (n = 30 patients), fat pad (n = 26
patients), synovium (n = 28 patients), trapezium (n = 6
patients) and blood (n = 19 patients) (Fig. 2). In cartilage,
we observed AEI that was comparable to that seen in
the original report; a mean AEI ratio (C/T) of 0.69,
equivalent to an average of 40.8% of the C allele in the
30 patients combined (P = 2 × 10−12). In fat pad and
synovium, we also observed a significant AEI, although
not as striking as that seen in cartilage: a mean AEI ratio
of 0.81, equivalent to 44.8% of the C allele, for fat pad
(P = 1 × 10−5), and a mean AEI ratio of 0.84, equivalent
to 45.7% of the C allele, for synovium (P = 8 × 10−4). In
trapezium, there was a non-significant (P = 0.18) mean
AEI ratio of 0.89, equivalent to 47.1% of the C allele,
whilst in blood, the mean AEI ratio was in the opposite
direction to that seen in the joint tissues: 1.19, which is
equivalent to 54.3% of the C allele (P = 0.006).
To highlight this difference in MGP AEI between tissues,
we plotted together the mean AEI values for the five tissue
types tested (Fig. 3a). This clearly shows the variation in
AEI between the tissues, with the risk allele showing re-
duced expression in cartilage toward increased expression
Fig. 1 Expression analysis of MGP in multiple tissue samples from patients and during chondrogenesis. a Expression of MGP was measured by
qPCR in OA patient cartilage, infrapatellar fat pad, synovium, trabecular bone, trapezium and blood. b Expression of MGP was measured in hip
cartilage from OA patients and patients with a neck-of-femur (NOF) fracture as controls, using RNA-sequencing data. c Expression of MGP
transcript isoforms (designated by their Ensembl database identification numbers) was measured using the same RNA-sequencing data. d
Expression of MGP during chondrogenesis of immortalised human MSCs. e Expression of MGP during chondrogenesis of bone marrow MSCs
from a human donor. In all panels, horizontal lines with bars show the mean ± standard error of the mean (SEM)
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in blood. To emphasise the variability of AEI in tissues
from the same patient, we next plotted the data for those
patients in whom we had studied two or more tissues
(Fig. 3b). There were 11 such patients, and there is clear
variability in the C/T ratio between the different tissues
tested for most of these, with patient 6597 demonstrating
particularly clearly the inter-tissue variability of the ratio.
Knockdown of MGP and matrix Gla protein
Having confirmed that the OA risk-conferring T allele of
rs4764133/C allele of rs4236 correlates with decreased
expression of MGP in joint tissues, we next modelled this
effect. Chondrocytes were isolated from the knee cartilage
of nine OA patients and then cultured in monolayer and
subjected to MGP knockdown by RNAi. Compared to the
effects of the scrambled siRNA control, siRNA targeting
MGP achieved a mean knockdown at the MGP mRNA
level of 93% (P < 0.0001) (Fig. 4a) with a 43% reduction at
the protein level (P < 0.01) (Fig. 4b, c).
We then assessed the effect of this knockdown on the
expression of a panel of genes that encompass cartilage
homeostasis: three chondroprotective/anabolic genes
(SOX9, COL2A1 and ACAN), five genes involved in car-
tilage hypertrophy (RUNX2, ALPL, COL1A1, COL10A1
and VEGFA), three catabolic genes (MMP13, ADAMTS4
and ADAMTS5) and the anti-apoptotic gene BCL2. De-
pletion of MGP correlated with a significant (P ≤ 0.05)
alteration in the expression of nine of the 12 genes
tested (Fig. 4d). There was a reduction in expression of
the longer isoform of RUNX2 (encodes runt-related
transcription factor 2; fold change = 0.67, P < 0.05), ALPL
(encodes alkaline phosphatase; fold change = 0.44, P <
0.01) and COL1A1 (encodes the α1 polypeptide chain of
type I collagen; fold change = 0.38, P < 0.01), and a sig-
nificant increase in the expression of SOX9 (encodes
Fig. 2 Allelic expression imbalance (AEI) analysis of MGP. AEI analysis of rs4236 was carried out in OA patient cartilage (n = 30) (a), infrapatellar fat
pad (n = 26) (b), synovium (n = 28) (c), trapezium (n = 6) (d) and blood (n = 19) (e). The y-axis for each plot shows the risk/non-risk (C/T) allelic
ratios, with a ratio < 1 indicating decreased expression and a ratio > 1 indicating increased expression of the C allele. Three technical repeats
were performed for each patient’s DNA and cDNA. The right panels show the mean values for DNA and cDNA from all patients combined, with
results represented by box-and-whisker plots, in which the lines within the box represent the median, the box represents the 25th to 75th
percentiles, and the whiskers represent the minimum and maximum values. P values were calculated using a Mann-Whitney 2-tailed exact test.
Individual patients are designated by their anonymised identification (ID) numbers
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transcription factor SOX-9; fold change = 2.83, P < 0.01),
COL10A1 (encodes the α1 polypeptide chain of type X
collagen; fold change = 2.17, P = 0.05), VEGFA (encodes
vascular endothelial growth factor A; fold change = 2.15,
P < 0.01), MMP13 (encodes collagenase 3; fold change =
1.18, P < 0.05), ADAMTS4 (encodes the aggrecanase A
disintegrin and metalloproteinase with thrombospondin
motifs 5; fold change = 2.17, P < 0.05) and BCL2 (encodes
apoptosis regulator Bcl-2; fold change = 1.51, P < 0.05).
Therefore, in this model system, depletion of MGP tran-
script and of its protein in OA knee cartilage had a signifi-
cant impact on genes encoding regulators and markers of
cartilage homeostasis.
Discussion
Our initial experiments assessed the expression of MGP in
multiple cell types from OA patients, with a focus on joint
tissues. There was expression in all five of the joint tissue
types tested, with the highest level being in cartilage. In a
comparison between OA and non-OA cartilage (NOF
samples), there was a greater expression in OA but a still
abundant expression in non-OA cartilage (mean TPM
values > 10,000 and > 5000, respectively). This implies that
the expression of the gene is not caused by OA but that its
level increases in response to OA, perhaps as an attempt
to halt the disease process. In our MSC chondrogenesis
models, we observed increased expression of MGP during
cartilage formation, reiterating that expression of the gene
is part of normal cartilage formation.
We next set out to replicate the MGP allelic expression
imbalance that the earlier study had reported on [8]. Using
MGP transcript SNP rs4236, we also showed that the OA-
risk conferring T allele of rs4764133 correlated with
reduced expression of the gene in patient cartilage. The
degree of AEI was highly comparable between our report
and the earlier study: 40.8% and 39.6% of the risk allele,
respectively. In that earlier report, the authors had also
observed reduced expression of the risk allele in subchon-
dral bone. We did not investigate this tissue in our
patients, but we did observe significant MGP AEI in fat
pad and synovium tissue and in the same direction as ob-
served in cartilage. However, the reduction in expression
of the risk allele was greater in cartilage; 40.8% of the risk
allele versus 44.8% in fat pad and 45.7% in synovium.
Overall, this implies that the functional consequence of
the OA risk mapping to this locus, namely reduced MGP
expression, is impacting on multiple knee and hip joint
tissues and that of those tissues tested; its effect is more
profound in cartilage. We also investigated MGP expres-
sion and AEI of MGP in blood from OA patients. Matrix
Fig. 3 Difference in AEI between tissues and within the tissues of the same patient. a The mean AEI value (± SEM) was plotted for each of the
five tissue types. b AEI analysis of 11 patients for whom samples were available from at least two tissues. Values are the mean ± standard
deviation (SD) AEI plotted for each individual in each tissue tested. Patients are designated by their anonymised ID number. In both plots, the
broken horizontal line indicates a C/T ratio of 1, which is indicative of no allelic imbalance
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Gla protein is synthesised by vascular smooth muscle
cells, where it inhibits vessel calcification [19], and by leu-
cocytes, where it may have a role in modulating immune
responses [20]. Expression of MGP was readily detectable
in our blood samples, and there was AEI but in the oppos-
ite direction to that seen in joint tissues, with an increased
expression of the OA risk allele. Our interpretation of this
is that the polymorphic DNA regulatory element that is
mediating MGP AEI is utilised by joint tissue and blood
cells but that it is acted on by different trans-acting factors
between the cell types, leading to opposite effects onMGP
expression. We have previously shown that the direction
and degree of AEI at an OA risk gene can vary between
different cell types that are concurrently collected from an
OA patient [21]. Our MGP results support this earlier ob-
servation and emphasise the probable complexity behind
the regulation of the expression of this gene. A search of
the GWAS Catalog (https://www.ebi.ac.uk/gwas/) did not
identify any associations between MGP polymorphisms
and ectopic calcification diseases of the vasculature.
Nevertheless, the functional effect that we have observed
in blood may prioritise rs4764133 and its correlating SNPs
for future analyses in such diseases.
In the GWAS that reported on MGP, rs4764133 was
associated with hand OA and, as we have done, the
investigators who reported that result then used joint
tissues from patients who had undergone knee and hip
arthroplasty to investigate MGP expression [8]. This is a
pragmatic decision in that these surgical procedures are
common, and as such, knee and hip joint tissues are
readily available for research. In our study, in addition to
knee and hip samples, we also managed to collect osteo-
chondral tissue from patients who had undergone a tra-
peziectomy. This involves the removal of the trapezium
joint that is located at the base of the thumb and within
the wrist. From a skeletal perspective, trapezium more
closely matches the phenotype used in the GWAS than
knees or hips, in that it is a hand joint. Furthermore, the
trapezium was one of the joints that was included in the
measure of hand OA in the genetic study. MGP was
expressed in our trapezium samples, but there was no
significant AEI when the six trapezium patients who we
Fig. 4 Effects of knockdown of MGP in primary chondrocytes from patients with OA. a MGP knockdown with siRNA targeting MGP (siMGP) was
carried out in cultured knee chondrocytes from nine OA patients, in comparison to the effects of a nontargeting siRNA control (siCONTROL). MGP
mRNA levels were measured by qPCR. Values represent the mean ± standard deviation (SD) fold change in expression compared to siRNA control,
with the data combined for the patients. b Representative results from immunoblotting demonstrating depletion of matrix Gla protein. GAPDH
was used as the loading control. c Fold change in matrix Gla protein level with the immunoblotting data combined for the patients. Values
represent the mean ± SD fold change compared to siRNA control. d Fold change in expression of genes following MGP knockdown, relative to
that with the siRNA control. Values represent the mean ± SD fold change in expression compared to siRNA control, with the data combined for
the patients. *P≤ 0.05; **P ≤ 0.01; ****P≤ 0.0001
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were able to study were combined. There was however a
trend and in the same direction as seen for the other
joint tissues, namely reduced expression of the OA risk-
conferring allele.
By knocking down the gene to deplete the levels of
matrix Gla protein, we finally modelled in cartilage chon-
drocytes the reduced expression of the MGP risk allele.
This had a significant effect on a range of genes involved in
cartilage homeostasis. We observed an increased expression
of the master chondrogenic transcription factor gene SOX9,
but this was not accompanied by an increased expression
of two of its principal target genes, COL2A1 and ACAN,
which code for the key structural components of cartilage,
type II collagen and aggrecan, respectively. Instead, we ob-
served an increased expression of the genes MMP13 and
ADAMTS4, which code for enzymes that degrade these
two proteins [22, 23]. We also observed an increased
expression of COL10A1 and VEGFA, which are markers of
cartilage ossification [24, 25]. These data suggest that deple-
tion of matrix Gla protein may have a detrimental impact
on chondrocytes, whereby several markers of catabolism,
hypertrophy and ossification are elevated. We hypothesise
that the observed increase in SOX9 expression may be a
response to counter this by boosting anabolism. There are,
however, some results from the knockdown experiment
that do not align with this interpretation. For example,
decreased expression of ALPL, which is also a marker of
cartilage ossification [26]. Overall however, recapitulating
the AEI by reducing the expression of MGP had clear
effects on chondrocyte marker genes and demonstrates
that, at least in this model system, alteration in the level of
matrix Gla protein has functional consequences.
In addition to our functional studies, mutations in MGP
have been described which cause calcification of the vascu-
lar system and cartilage. Keutel syndrome arises from
MGP mutations and manifests as vascular calcification
with skeletal abnormalities, and an MGP-deficient mouse
model displays a similar phenotype [27]. Vitamin K, and
MGP functionality, was implicated in OA when plasma
vitamin K concentrations were correlated with radio-
graphic signs of OA or pathological changes to the joint
[28, 29]. Furthermore, MGP polymorphisms were signifi-
cantly associated with OA in a candidate gene study inves-
tigating vitamin K supplementation in deficient individuals
[30]. Taken together, there is now a growing body of
evidence to support further exploration of MGP and its
functional role in cartilage and matrix biology, and in the
ectopic mineralisation process.
Conclusions
We have replicated and expanded on the study that cor-
related expression of MGP with the OA association sig-
nal marked by SNP rs4764133. We confirm that the OA
risk-conferring allele of this SNP demonstrates reduced
expression in cartilage and in other joint tissues. We also
show that in peripheral blood, this effect is reversed,
highlighting complexity in the regulation of expression
of the gene. In our RNA-seq data, MGP was more highly
expressed in OA versus non-OA cartilage. Combining
this observation with our AEI observations, we conclude
that in response to OA, chondrocytes need to express
more MGP but that in an individual who has inherited
low expressing alleles of MGP, their capacity to boost
the gene’s expression is attenuated. As such, the disease
is more likely to progress and less likely to resolve in
these individuals. Our recapitulation by RNAi of the
functional effect of this genetic signal had clear impacts
on chondrocyte gene expression. As such, MGP knock-
down is an appropriate model that could now be
exploited to assess the capacity of interventions to over-
come the genetic susceptibility at this locus.
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